Last reviewed · How we verify
OPC-34712
OPC-34712 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.
OPC-34712 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders. Used for Major depressive disorder, Bipolar disorder.
At a glance
| Generic name | OPC-34712 |
|---|---|
| Also known as | Generic Name: Brexpiprazole, Brexpiprazole |
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Drug class | 5-HT7 receptor antagonist |
| Target | 5-HT7 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
The drug selectively blocks 5-HT7 receptors, which are involved in circadian rhythm regulation, mood, and cognitive function. By antagonizing these receptors, OPC-34712 may improve symptoms in conditions characterized by circadian dysfunction and mood disturbance. This mechanism differs from traditional antidepressants and may offer a novel approach to treatment-resistant psychiatric conditions.
Approved indications
- Major depressive disorder
- Bipolar disorder
Common side effects
- Headache
- Nausea
- Insomnia
- Dizziness
Key clinical trials
- Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia (PHASE3)
- Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (PHASE3)
- Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type (PHASE2, PHASE3)
- Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD) (PHASE2, PHASE3)
- Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type (PHASE3)
- Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148 (PHASE3)
- Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder (PHASE4)
- Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |